Barely Significant
← all excerpts

mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin-mediated amyloidosis.

Muscle Nerve · 2020 · PMC7540053 · PMID 32654212

Europe PMCDOI
1
hedged sentence
0.0510
closest p · 1.0× alpha
0.0510
boldest claim

The sentences

approached significanceP = .051so close (0.05 < p ≤ 0.1)
In addition, the individual assessment of ulnar CMAP significantly favored inotersen versus placebo ( P = .015); however, the individual assessments of fibular CMAP approached significance ( P = .051), whereas the individual assessments of sural SNAP, tibial CMAP, and ulnar SNAP amplitudes did not reach a significant difference (Figure 2 ). 3.3 Lower limb function and components response Changes from baseline in the total lower limb function score and each of its three components indicated significantly less neuropathic progression in patients treated with inotersen compared with those receiving placebo.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.